Acquired immunodeficiency syndrome (AIDS) is one of the most widespread, catastrophic, and incurable diseases among humans in the world. According to a report published by the World Health Organization (WHO) in 2013, deaths caused by HIV ranked sixth in the total number of deaths in the world. Human immunodeficiency virus (HIV) presents itself as a complex mixture of symptoms, all related to severe immune compromise, while AIDS is an advanced stage of HIV infection. Globally, the number of annual deaths caused due to HIV/AIDS declined from 2.3 million in 2005 to 1.5 million in 2013, according to a report on AIDS published by the UN. For the treatment of AIDS/HIV, anti-retroviral therapy (ART) is used, which is a combination of medicines that have proved to be effective for years. Anti-retroviral therapy prevents the multiplication of human immunodeficiency virus, and thereby, reduces virus in the patient’s body, protecting the immune system. HIV regimen initially includes three anti-retroviral drugs from at least two different drug classes.
If employed on time, anti-retroviral therapy prevents HIV infection from culminating into AIDS; the therapy increases the lifespan of the patient and also significantly reduces the risk of transmission of the virus. Pharmaceutical companies are focusing on research and development of novel drugs that can prove to be a long-term cure for HIV virus and can forever suppress the virus throughout the life of an individual. Thus, anticipated approval of several new drugs for treatment of AIDS in the near future is poised to propel the growth of the acquired immunodeficiency syndrome treatment market during the forecast years.
The acquired immunodeficiency syndrome treatment market can be segmented based on drug class, distribution channel, and region, as shown in the following:
Acquired Immunodeficiency Syndrome (AIDS) Market, by Drug Class:
Acquired Immunodeficiency Syndrome (AIDS) Treatment Market, by Distribution Channel Class:
The acquired immunodeficiency syndrome treatment market can be divided into drug therapy, gene therapy, cell therapy, and others. Based on disease indication, the acquired immunodeficiency syndrome treatment market can be categorized into genetic disorders, rare cancer, rare blood disorders, autoimmune disorders, infectious diseases, and others. In terms of region, the acquired immunodeficiency syndrome treatment market can be classified into Asia Pacific (APAC), Europe, Middle East & Africa (MEA), North America (NA), and Latin America (LA).
Key players in the acquired immunodeficiency syndrome treatment market are Shire Plc., AstraZeneca Eli Lilly and Company, Merck KGaA, Sanofi, Pfizer, Inc., Amgen Inc., Biogen Inc., Novartis AG, Actelion Ltd, Daiichi Sankyo Company, etc. Intense competition is driving acquisitions and in-licensing agreements as companies are striving to expand and diversify their product pipeline. For instance, Shire Plc., acquired Dyax Corp in 2015 in order to expand the former’s product offerings for acquired immunodeficiency syndrome treatment. Strategic partnerships and alliances are common as companies are aiming to synergize their programs and develop combination acquired immunodeficiency syndrome therapies.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
The regional analysis covers:
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Please fill the Request TOC form below.
Make an enquiry before buying this Report
Please fill the enquiry form below.